ERBB2 and neoplasm: Tumor-targeting monoclonal antibodies (e.g., anti-CD20, anti-HER-2, anti-GD2, anti-EGFR, and anti-GD2) or bispecific antibodies to induce antibody-dependent cell-mediated cytotoxicity (ADCC)